<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">All subjects survived the study, and there were no reported serious adverse events (AEs). None of the reported AEs (TableÂ 
 <xref rid="Tab2" ref-type="table">2</xref>) required adjustment, interruption or discontinuation of treatments. There were six moderate AEs, and 66 mild AEs. No AEs were ongoing at the 1-year follow-up visit. No AEs were classified as definitely related to study treatment. The most commonly reported AEs were headache (18 mild and one moderate), and fatigue (19 mild), classified as possibly related to treatment. 
</p>
